EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study
Vlad Ratziu, Mary E. Rinella, Brent A. Neuschwander‐Tetri, Eric Lawitz, Douglas Denham, Zeid Kayali, Aasim Sheikh, Kris V. Kowdley, Taddese Desta, Magdy Elkhashab, Jeffery DeGrauw, Bryan Goodwin, Alaa Ahmad, Nathalie Adda
Topics & Concepts
PlaceboMedicineInternal medicineGastroenterologyTolerabilitySteatohepatitisNauseaClinical endpointAdverse effectVomitingCirrhosisObeticholic acidRandomized controlled trialFatty liverAgonistPathologyReceptorAlternative medicineDiseaseLiver Disease Diagnosis and TreatmentLiver Diseases and ImmunityInflammatory Bowel Disease